Abilify Bellwethers Settle Right Before Trial Over Impulsive Gambling-Sexual Activity Claims

“With global settlement talks now in place less than a week later”

By Mark A. York (May 3, 2018)

Will Abilify MDL Settle By September 15, 2018?

(Mass Tort Nexus Media) The first pool of three bellwether trial plaintiffs have settled just before trials started in the Abilify MDL 2734 in front of Judge Casey Rodgers earlier this week, see Abilify Settlement Order Re First Bellwether Trial Pool Cases Entered April 28, 2018 (www.masstortnexus.com), related to the antipsychotic drug Abilify. The plaintiffs claimed after being prescribed the drug, Abilify made them gamble compulsively. All three cases were settled against the drug makers  Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, for undisclosed amounts. The three Florida residents’ cases were scheduled for trial starting in June as bellwether trials, for case information see the Mass Tort Nexus Abilify briefcase, ABILIFY-MDL-2734-USDC-MDL-Florida (Briefcases/Drugs).

The Abilify multidistrict litigation includes 808 cases, as of April 16, and as of May 2, 2018 there is a Global Settllement Order in place, see Abilify MDL 2734 Global Settlement Order No. 1 Entered May 2, 2018, where Judge Rodgers gave the parties 120 days to finalize a framework of a global settlement, including a first phase outline of what will be classified as “no pay” cases, with these cases to be identified within 14 days of the global order or by May 16, 2018. Upon identification of the no pay cases, they will be removed from the MDL.

Also of note is language in the April 28th settlement order for the three bellwether trials, is a requirement that defendants must pay the settlement proceeds to plaintiffs, who in turn must execute full release and then, within 10 days, parties must file a stipulation of dismissal. Judge Casey has ordered the three cases to remain on the trial docket until the stipulated dismissals are filed. This appears to be another federal judge asserting direct control over the often lengthy and drawn out settlement talks  in MDL’s across the country. Judges are now moving cases toward settlement or setting them for trial, pursuant to the JPML rules of civil procedure outline.

ABILIFY BACKGROUND

The Abilify litigation is against defendants Japanese drugmaker Otsuka and Britsol-Myers Squibb, which marketed the drug in the U.S. until 2013 and related to plaintiffs being prescribed Abilify, an anti-psychotic medication commonly prescribed to treat a variety of mental disorders, which caused impulse control problems in users. The two primary impulse control claims are “impulsive gambling” and “uncontrollable sexual urges” with several plaintiffs claiming to have lost millions of dollars in gambling sprees brought on after consuming Abilify, while never having gambled before. The other control issue is “inability to control sexual urges or engaging in sexual promiscuity” resulting in ruined personal relationships and adverse health conditions, as well as related financial consequences.

 

 

 

 

 

 

 

 

 

 

Aripiprazole is available under the brand names Abilify, Abilify Maintena, Aristada, and also as generics. A search of the FDA Adverse Event Reporting System (FAERS) database and the medical literature in the 13 years since the approval of the first aripiprazole product (Abilify) in November 2002 identified a total of 184 case reports in which there was an association between aripiprazole use and impulse-control problems.

May 5, 2016 FDA Drug Safety Notice: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)

ABILIFY (aripiprazole) – FDA: Adverse Reactions

https://www.accessdata.fda.gov/…/021436s038,021713s030,021729s022,021866s023…

Seizures/Convulsions. 5.10 Potential for Cognitive and Motor Impairment. 5.11 Body Temperature Regulation. 5.12 Suicide. 5.13 Dysphagia. 6. ADVERSE REACTIONS. 6.1. Clinical Trials Experience. 6.2. Postmarketing Experience. 7. DRUG INTERACTIONS. 7.1. Drugs Having Clinically Important Interactions with Abilify.

THE ABILIFY MDL

On October 3, 2016, the JPML consolidated pretrial proceedings for In Re: Abilify (Aripiprazole) Products Liability Litigation, MDL No. 2734, in the US district Court Northern district of Florida. The transferred actions share factual issues arising from allegations that Abilify (aripirazole), an atypical anti-psychotic medication commonly prescribed to treat a variety of mental disorders, can cause impulse control problems in users. All the actions involve factual questions of whether Abilify was defectively designed or manufactured, whether defendants knew or should have known of the alleged propensity of Abilify to cause compulsive gambling behaviors in users, and whether defendants provided adequate instructions and warnings with this product.

These cases were  assigned to the Honorable M. Casey Rodgers for coordinated discovery and pretrial matters.

Abilify Linked to Compulsive Behaviors

Details of the three Abilify settlements were not made public. But include payment by the defendants to the plaintiffs, as well as apparently opening the door for a full global settlement of the remaining 800 plus cases.

Introduced in 2002, Abilify became a blockbuster drug, generating nearly $8 billion a year by 2013. The following year, it was the top-selling drug in the U.S. Sales fell in 2015 when the first generic versions of the drug were approved.

The drug is prescribed to treat psychiatric conditions including bipolar disorder, schizophrenia and major depression.

Off-label uses include anxiety disorders, dementia and post-traumatic stress disorder. The drug has been linked to severe, compulsive behaviors, mainly gambling, sex and shopping.

Gambling Warning Added in 2016

About a week before the settlement was reached, the plaintiffs sought a court order allowing them to secure documents from Otsuka regarding Rexulti, the drug that was introduced when Abilify’s patent expired.

Plaintiffs argued in court filings that Rexulti had the same mechanism of action. The company didn’t begin to warn that Rexulti could cause compulsive gambling until January of this year. That warning was added to the Abilify label in the U.S. in August 2016.

The cases that settled are plaintiffs, Jennifer Lilly, David Viechec and Fanny Lyons.

Lyons’ lawsuit was scheduled to start trial June 18. According to court filings, she began taking Abilify around January 2009 and soon began compulsive gambling. She stopped taking the drug in January 2014 and stopped gambling soon after that. She claims to have lost more than $75,000.

Viechec was scheduled to have his case heard by a jury beginning Aug. 6. According to court filings, he was prescribed Abilify for bipolar symptoms from 2012 until late 2016. He also claimed to have lost more than $75,000 from gambling, which stopped after he stopped taking the drug.

Lilly’s case was scheduled to start trial on Aug. 27. According to her lawsuit, she took Abilify from 2003 to 2016. Her lawsuit claims unspecified gambling and other losses, including the loss of the ability to earn money.

The settlement of the three initial trials and entry of a global settlement order less than a week later seems to point to a decision by Bristol Myers and Otsuka that perhaps settling now versus waiting until adverse material and testimony come out at trial is the prudent legal strategy at this point.

Congratulations to Judge Casey for putting a timer on the settlement discussions and directing legal traffic in his MDL docket.

 

 

Read More

HeartStart MRx Defibrillator Emerging Litigation

Emerging HeartStart MRx Defibrillator Litigation

 

 

 

 

 

 

 

 

 

 

HeartStart MRx Defibrillator by Philips Electronics: Class I Recall –

Defects in Gas Discharge Tubes May Cause Device Failure

2018 FDA Communication Excerpt:

ISSUE: Philips is recalling the HeartStart MRx Defibrillator due to a defect in the device’s Gas Discharge Tube (GDT). The GDT has micro cracks which allows internal gasses to escape and causes the tubes to not function as expected. This also permits an electrical current surge to cross the device’s designated resistors, which will damage the resistors and prevent the device from working while in automated external defibrillator (AED) mode.

As a result of this GDT defect, the HeartStart MRx may fail at any time, including when delivering repeated shocks in AED mode, or during the periodic Operational Check outlined in the device’s Instructions for Use. If the device is used in AED mode after failure, the device will not deliver patient therapy. Continued use of the device in AED mode after failure may lead to serious patient injury or death.

To Learn More About the HeartStart MRx Defibrillator Emerging Litigation:

The Emerging  HeartStart MRx Defibrillator Emerging Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494. 

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Course attendees will receive the benefit of a step by step analysis of the Emerging HeartStart MRx Defibrillator Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including Michael Brady Lynch>

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

Read More

Kayexalate Emerging Litigation

Emerging Kayexalate Litigation

Kayexalate: An emerging litigation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Kayexalate, made by Concordia Pharmaceuticals, Inc. was first approved by the FDA subsequent to New Drug Application 011287.

September 2017 : FDA is recommending that patients avoid taking the potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) at the same time as other medicines taken by mouth. A study found that sodium polystyrene sulfonate binds to many commonly prescribed oral medicines, decreasing the absorption and therefore effectiveness of those oral medicines.

A study was conducted in the laboratory, called an in vitro study, to evaluate the binding potential for certain administered medicines commonly taken together with sodium polystyrene sulfonate. These medicines included certain:

Blood pressure medicines

Antibiotics

Seizure Medications

Blood Thinner Medication

Furosemide

By reducing or eliminating the effectiveness of other drugs, patients may be more likely to suffer adverse events intended to be controlled by the effected drugs.

Prior to the September 2017 FDA action, the Kayexalate label included warnings related to the concomitant use of several drugs however, these warnings did not include a significant number of drugs now found to be potentially harmful when used in combination with Kayexalate.

To Learn More About the Emerging Kayexalate Litigation:

The emerging Kayexalate Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging Kayexalate Litigaton, using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including Michael Brady Lynch>

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

Read More

Absorb GT1 Bioresorbable Vascular Scaffold Potential Litigation

Absorb GT1 Bioresorbable Vascular Scaffold Potential Litigation     

 

  

 

Absorb GT1 Bioresorbable Vascular Scaffold made by Abbot Vascular gained FDA Approval in July of 2016 subsequent to Premarket Approval Application (PMA: P150023)

Intended Use: The Absorb GT1 Bioresorbable Vascular Scaffold (BVS) is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.

FDA Communication Excerpt:

October 31, 2017 : The FDA is issuing this update to our March 18, 2017 letter to health care providers to inform the health care community that interim study results through three years from the pivotal clinical trial (ABSORB III) continue to show an increased rate of major adverse cardiac events and BVS scaffold thrombosis in patients receiving the Absorb GT1 Bioresorbable Vascular Scaffold (BVS), when compared to patients treated with the approved metallic XIENCE drug-eluting stent.

 

To Learn More About the Emerging Absorb GT1 Bioresorbable Vascular Scaffold Potential Litigation:   

The emerging GT1 Bioresorbable Vascular Scaffold Potential Litigation  will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

 

 

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Course attendees will receive the benefit of a step by step analysis of the emerging GT1 Bioresorbable Vascular Scaffold Potential using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including Annesley DeGaris>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

 

 

Read More

New Breast Implant Emerging Litigation

Emerging New Breast Implant Litigation     

 

 

 

 

 

 

 

 A recent study published in JAMA Oncology concluded that  found that silicone breast implants with a textured surface are 400-times more likely to cause a rare type of cancer compared to silicone breast implants with a smooth surface.

Approximately 1 out of every 26 women in the United States have breast implants.

The primary makers of breast implants approved for use in the United States include:

Allergan, Inc.

Ideal Implant, Inc.

Mentor World Wide, LLC

Sientra, Inc.

To Learn More About the newest Emerging Breast Implant Litigation

The emerging New Breast Implant Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

 

 

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Course attendees will receive the benefit of a step by step analysis of the emerging New Breast Implant Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including CNN Legal Analyst Mark O’Mara>

 

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

 

 

 

Read More

Individual Plaintiff Opioid Cases – An Emerging Litigation

Individual Plaintiff Opioid Cases Now Emerging in The Opiate Litigation

 

 

 

 

 

 

 

 

 

 

Most discussions in the legal community have focused on the “entity” plaintiffs thus far and these entity cases certainly have merit however, our researchers believe the largest number of potential plaintiffs with viable cases against the opioid manufacturers are those claims related to individual plaintiff injuries and deaths.

Learn More About the Opioid Individual Case Emerging Litigation

The  Opioid Individual Case Emerging Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Your PI Firm Has Already Represented Individuals Who May Now Have Viable Opioid Cases

Given the fact that the first opioid prescription a person ever receives often occur due to an auto accident, a work related injury or another injury which results in the filing of a personal injury case, your firm has already represented numerous individuals who now have claims related to opioids. Sign these individual plaintiffs you already have before someone else does

Unlike the entity cases which as a general rule name a host of manufacurers as well as distributors as defendants, some individual opioid cases may be brought against a single manufacturer while others may be filed based on legal theories that will require naming some or all of the alleged “opioid conspirators”.

The “individual case” opioid litigation will be different than a typical mass tort litigation involving a pharmaceutical product. Different claims will exist against different manufacturers and arise from different causes.

The single most important first step for any law firm considering accepting clients with individual opioid cases will be to learn how to properly qualify clients.

Examples of Opioid Claims Arising from FDA Actions

Opana ER: June 2017  U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks.

Codeine and Tramadol Can Cause Breathing Problems for Children

FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women issued on April 20, 2017.

These medicines can cause life-threatening breathing problems in children. Some children and adults break down codeine and tramadol into their active forms faster than other people. That can cause the level of opioids in these people to rise too high and too quickly.

January 2018 FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older

The U.S. Food and Drug Administration (FDA) is requiring safety labeling changes for prescription cough and cold medicines containing codeine or hydrocodone to limit the use of these products to adults 18 years and older because the risks of these medicines outweigh their benefits in children younger than 18.

The Individual Opioid cases (arising from a given cause) listed above are only a fraction of the universe of these types of opioid cases.  Attend the May Four Days to Mass Tort Success Course for a broader coverage of the individual case opioid litigation.

Mass Tort Nexus is also hosting a national “Opioid Crisis Summit” July 21-22, 2018 here in Fort Lauderdale

This event will be unlike ANY other opioid conference ever presented to attorneys. CNN, Associated Press, STAT NEWS (The Boston Globe), The Sun-Sentinel, ABC and NBC will be here to cover this event because never before has such a comprehensive group of experts been assembled to explain how the Opioid Crisis began and how it has affected our country. Leading politicians, medical doctors, treatments centers, academics and attorneys will come together to tell the story of what happened from their vast experience in dealing with this crisis, for more than two decades.

WHY DO YOU NEED TO ATTEND THIS EVENT?

Contrary to popular belief, it is not too late to acquire entity cases (state, county, city, union, private insurers, etc.) There are an estimated 10,000 entity cases and less than 1% have been signed. Mass Tort Nexus has the data for every county in the country, along with an index score to arm you with the information to write accurate complaints and customize them in great detail.

The universe of individual cases will potentially be in excess of one million plaintiffs. Over 90 million Americans were prescribed opioids in the last year alone and there is not one segment of society that has not been affected. The only litigation that compares to it in size and scope is the tobacco litigation; however, there is one big difference – the opioid litigation is likely to resolve far more quickly. We will reveal the reasons why. Our keynote speakers include Ohio Lt. Governor Mary Taylor and Dr. Rahul Gupta, Director of Public Health, State of West Virginia and others with real time, day to day experience in dealing with opioid crisis as well as providing solutions.

For complete information on this major Opioid Summit and the nationally prominent guest speakers – follow the link below:

Opioid Crisis Summit by Mass Tort Nexus- July 21-22, 2018 Summit link and Information

 

 

 

 

Read More

NeuroBlate Probe Emerging Litigation

Emerging NeuroBlate Probe Litigation

  

 

 

 

 

 

 

 

 

 

 

 

The NeuroBlate probe made by Moneris Medical, Inc. is a device used during various types of complex neurological surgeries.

March 2018 FDA Communication Excerpt:

ISSUE: The FDA is providing preliminary information about the potential for unintended heating and patient injury with use of the Monteris Medical NeuroBlate probe, which is part of the NeuroBlate System, and bringing to your attention a Class I recall for the device.

A Class I recall is the most serious type of recall and is issued when use of the device may cause serious injuries or death. Monteris issued three product advisories between October and December 2017, which were part of the Class I recall; however, the FDA has concerns that the information provided by Monteris has not sufficiently mitigated the risk of unintended probe tip heating. We are working with the manufacturer to address these concerns.

The device is currently the subject of a voluntary recall which was initiated by the firm, and classified as a Class I Recall by the FDA, due to several instances of unintended heating and damage to the probe, which may have resulted in unintended damage to surrounding brain tissue. The damage to the probe appears to have been caused by an interaction between the thermocouple in the probe, and the MRI environment. These events occurred independent of laser energy delivery, and have been associated with damage to the tip of the probe implanted within the brain (e.g., charring, release of carbon dioxide).

To Learn More About the Emerging NeuroBlate Probe Litigation:

The Emerging Moneris Medical NeuroBlate Probe Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

 For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the Emerging NeuroBlate probe Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements from some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course, see James Onder of The Onder Firm in St. Louis, MO comments below>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

Read More

 New Gadolinium Imaging Contrast Agent Emerging Litigation   

Emerging New Gadolinium Imaging Contrast Agent Litigation   

 

Gadolinium Imaging Contrast Agent In The Brain

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lawsuits related to Gadolinium Contrast Dyes have previously been consolidated in MDL 1909 on June 6th, 2008. The current issues related to Gadolinium Contrast Dyes are different from those litigated in MDL 1909.

MDL 1909 Defendants: General Electric Company, GE Healthcare, Inc., and GE Healthcare Bio-sciences Corp. (the GE defendants), and Mallinckrodt, Inc.

FDA December 2017 After reviewing available data, the FDA recommended that radiologists consider how much gadolinium might be left behind in a patient’s body when selecting a gadolinium-based contrast agent [GBCA] for an MRI.

The current primary concern related to Gadolinium Contrast Agents relates to the buildup in the brain,  of certain substances contained in these agents.

Gena Norris, wife of actor Chuck Norris recently brought a lawsuit alleging that she fell ill after exposure to gadolinium used in an MRI.

Gadolinium Contrast Agents include:

Ablavar (gadofosveset trisodium)

Dotarem (gadoterate meglumine)

Eovist (gadoxetate disodium)

Gadavist (gadobutrol)

Magnevist (gadopentetate dimeglumine)

MultiHance (gadobenate dimeglumine)

Omniscan (gadodiamide)

OptiMARK (gadoversetamide)

ProHance (gadoteridol)

 To Learn More About the Emerging New Gadolinium Contrast Agent Litigation:    

The emerging New Gadolinium Contrast Agent will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

 

 Course attendees will receive the benefit of a step by step analysis of the emerging New Gadolinium  Contrast using these primary metrics:

 

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

 

 

Read More

 Imodium OTC Emerging Litigation

Emerging Imodium-Over The Counter Litigation

 

IMODIUM PRODUCTS EMERGING LITIGATION

 

 

 

 

 

 

 

 

 

 

 

Imodium (LOPERAMIDE HYDROCHLORIDE) Products include:  Imodium, Imodium A-D, Imodium A-D EZ Chews. Imodium Multi-Symptom Relief . These products are manufactured and or marketed by Janssen Pharmaceuticals  and Johnson and Johnson Consumer Inc. Imodium has been available for over two decades and is one of the most commonly used medications for the treatment of diarrhea symptoms.

The FDA issued a drug safety advisory warning that many people are experiencing serious heart problems after taking high doses of Imodium or taking Imodium in combination with other medications that interact with the drug.

Imodium, Imodium A-D, Imodium A-D EZ Chews and Imodium Multi-Symptom Relief

Many of the drugs that are believed to negatively interact with Imodium are commonly used in combination with Imodium.

A partial list of drugs which are believed to negatively interact with Imodium include:

Tagamet HB (cimetidine) – treat heartburn, GERD symptoms

Zantac (rantidine) – treat heartburn, GERD symptoms

Prevpac – proton-pump inhibitor; used to treat heartburn, acid reflux

Biaxin (clarithromycin) – antibiotic

E.E.S., Ery-Tab, Eryc, Eryped, PCE (erythromycin) – antibiotic

Lopid (gemfibrozil) – treats high cholesterol

Onmel, Sporanox (itraconazole) – anti-fungal medications

Ketoconazole (generic only) – anti-fungal medication

Nuedexta (quinidine) – used to treat mental/mood disorders

Qualaquin (quinine) – anti-malaria drug; also used to treat nocturnal leg cramps

Kaletra, Norvir, Technivie, Viekira Pak (ritonavir) – anti-HIV treatment

To Learn More About the Emerging Imodium OTC Litigation:

The emerging Imodium OTC  Litigation will be used as a case study in the May 18-21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging Imodium and Similar Products Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course have endorsed Mass Tort Nexus and the course curriculum, including Annesley DeGaris below>

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

Read More

Vascular Solutions, Inc. Emerging “Venture Catheters” Recall Litigation

Emerging Venture Catheters Recall Litigation

Vascular Systems, Inc. Venture Catheter Litigation

 

 

 

 

 

 

 

 

 

A Class 1 FDA Recall has been issued by the FDA related to certain Catheters manufactured by Venture Solutions, Inc. between 2015 and 2017.

      FDA Communication Excerpt:

“Vascular Solutions, Inc. is recalling the Venture catheter because there is a risk of the catheter tip splitting or separating during use. Excess material at the tip of the catheter may separate and could enter the patient’s bloodstream. This can result in serious adverse health consequences such as the development of blood clots, embolism of the excess material to vital organs, or death”

Learn More About the Emerging Venture Catheters  Recall  Litigation

The emerging Venture Catheters Recall will be used as a case study in the May 18-21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

 

Course attendees will receive the benefit of a step by step analysis of the emerging  Venture Catheters Recall  Litigation using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

 

See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

Read More